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Abstract
Genomic research has the capacity to generate a wide array of findings that go beyond the goals of
the study—usually referred to as “incidental findings.” The evolving consensus of researchers,
participants, and expert panels is that at least some incidental results should be made available to
participants. However, there are a number of challenges to discussing these issues with
participants and ascertaining their preferences, including the complexity and magnitude of the
relevant information. Believing that usual models of informed consent are not likely to be
effective in this context, we identify four approaches that investigators and IRBs might consider:
traditional consent, staged consent, mandatory return, and outsourcing. Each has advantages and
disadvantages compared with the other options, and which one is selected for a given project will
depend on a mix of practical and normative considerations that are described in this paper.
Genomic research—including whole genome sequencing and whole exome sequencing—
has a growing presence in contemporary biomedical investigation. The capacity of
sequencing techniques to generate results that go beyond the primary aims of the research—
historically and in this paper referred to as “incidental findings”a— has created considerable
discussion as to how this information should be handled, i.e., whether incidental results
should be returned, and if so, which ones?1 We previously reported strong support among
genomic researchers for the return of medically actionable data, and substantial support for
offering participants findings related to reproductive choices, pharmacogenetics, and highly
penetrant disorders without available clinical interventions.2 Others have reported
comparable results,3 and a number of expert groups have taken similar positions.4
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Participants in genetic research have been reported to be extremely interested in the receipt
of most classes of genetic findings.5
Important questions remain to be answered about how incidental findings may be identified
and returned to research participants. Some genomic studies involve interrogation of large
parts of the genome, making identification of incidental findings quite likely. However, in
many sequencing studies data can be filtered selectively, permitting investigators to control
the extent to which incidental findings are likely to be identified.6 Whether genomic
researchers will ultimately be deemed to have an obligation to search for certain categories
of incidental findings, and how extensive those categories may be, remains undetermined.
Similarly uncertain is the extent to which participants will be given the choice of which
types of findings they desire to receive, although making such options available has been
widely endorsed.7 In studies in which identification of incidental findings is probable and
investigators undertake to make them available to participants, questions about how best to
inform participants and obtain their consent inevitably arise.8
Federal regulations governing most human subjects research in the United States require the
disclosure of “the procedures to be followed” in the research as part of the informed consent
process.9 It seems reasonable to assume—and indeed, many commentators have
concluded10—that the prospect of incidental findings becoming available and how they will
be dealt with is one of the procedures about which genomic investigators will be expected to
inform participants. Moreover, the regulations also mandate disclosure of “reasonably
foreseeable risks” and “any benefits to the subject or to others which may reasonably be
expected”11; to the extent that the availability of incidental findings may evoke both risks
and benefits for participants, they will need to be revealed as well.12 Other potentially
relevant sections of the regulations relate to disclosure of “the extent, if any, to which
confidentiality of records identifying the subject will be maintained” and “additional costs to
the subject that may result from participation.”13 These are issues that genomic investigators
and institutional review boards will need to consider in drafting and reviewing informed
consent procedures for genomic research.
aHistorically, the relevant policy discussion has used the term “incidental” to denote findings that were beyond the primary aim of the
research. The idea was that, in the course of investigating disease A, a researcher might stumble upon a finding associated with disease
B. Some genomic findings are “incidental” in that sense. But the new sequencing technologies, which entail the application of filters
to raw sequence data, are moving us rapidly toward a time when, while one is investigating A, one can, at virtually no additional cost,
look for variants associated with diseases A through Z (E. Parens et al, “Incidental Findings in the Era of Whole Genome
Sequencing?” The Hastings Center Report 43, no. 4 [2013]: 16–9). When one is actively “filtering” or searching for mutations in
genes other than those associated with the primary aim of the investigation, we think that the term “secondary” is more accurate than
“incidental.” Indeed, in its recent report, Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings in
the Clinical, Research, and Direct-to-Consumer Context (Washington, DC: December 2013 http://www.bioethics.gov/), the
Presidential Commission for the Study of Bioethical Issues argues for the importance of making the distinction between incidental and
secondary findings. However, given that "incidental findings" is the term that was used in the studies described below and remains the
dominant term in the literature (see L. G. Biesecker, “Incidental Variants Are Critical for Genomics,” American Journal of Human
Genetics 92 (2013): 648–51 and J. P. Evans, “When Is A Medical Finding “Incidental”?” Genomics in Medicine 15, (2013): 515–16),
we use it in this paper, despite its limitations.
Appelbaum et al. Page 2













Challenges to Obtaining Informed Consent to the Return of Incidental
Findings
On its face, obtaining informed consent regarding the possible discovery of incidental
findings—in compliance with the federal regulations, as well as the widely recognized
ethical duties on which the regulations are based—presents a number of challenges. Because
in many studies the range of potential results will be so great as to preclude listing specific
possibilities, broader groupings (often referred to as “bins”14) may need to be used. If
participants are given the option of consenting to the return of data in some but not all of
these bins, they will need to be told about and to select among types of conditions by
probability of developing the disease, severity of disorder, availability and effectiveness of
interventions, reproductive implications, or other dimensions. In addition, given that
investigators prospectively discussing the return of incidental results with participants will
know neither the likely findings nor their potential implications, the discussion of possible
risks and benefits will lack specificity and may necessarily be speculative, i.e., it will reflect
the unknowns inherent in this process. Insofar as genomic data often carry implications for
family members in addition to participants, this too may need to be described to participants.
Investigators, most of whom will not have dealt with these issues before, will thus face
considerable challenges in framing meaningful disclosures for research participants.
To assist genomic investigators in this task, we undertook to identify the elements that
should be included in the informed consent process related to incidental findings.15 We did
this by surveying a large number of genomic researchers (n=241), and by conducting in-
depth interviews with a smaller number of researchers (n=28) and genomic research
participants (n=20). There is considerable face validity to this approach: common law
standards for informed consent in clinical care look either to the usual practice of physicians
(“professional standard”) or to the information needs of patients (“lay standard’) in
determining the required scope of disclosure.16 Although consent in research settings
operates with an overlay of regulatory requirements, ascertaining the views of investigators
and participants remains meaningful. In our survey and interviews, we presented our
respondents with options regarding the types of information about incidental findings that
might be disclosed to research participants and asked whether they thought each item should
be included in informed consent disclosures. Options were taken from an exhaustive
literature review on incidental findings. We also queried respondents on what other pieces of
information should be included.
Our findings with regard to risks and benefits of returning incidental findings showed that a
majority of the researchers surveyed endorsed discussion of a wide range of risks (e.g.,
negative psychological responses, false negative or false positive findings) and benefits
(e.g., identification of treatable disorders, enhanced life-planning ability). The genomic
research participants interviewed were even more strongly in favor of disclosure. In
addition, respondents were just as strongly in favor of discussing information about the
possible impact of incidental findings on family members; protections for the confidentiality
of the findings; procedures related to the return of incidental data should participants
become impaired or deceased; whether incidental findings generated in subsequent research
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or as a result of advances in interpretation would be offered to participants; and the
circumstances, if any, in which participants’ choices about return of incidental findings
could be overridden. Additional categories of information suggested for discussion included
the possibility that incest or misattributed paternity would be detected and the extent to
which the data would be shared with other researchers.
Based on the responses of investigators and research participants to our survey and
interviews, even taking into account a potential tendency to endorse whatever options were
presented, it was clear that both parties expect a large amount of information about possible
return of incidental findings to be exchanged. In the in-depth interviews, though, researchers
and participants alike expressed concern over the ability of participants to attend to and
comprehend such extensive disclosures, especially in the context of additional disclosures
regarding the study for which sequencing was to be performed. In addition, when
researchers were asked how much time they were willing to devote to informed consent
regarding incidental findings, 44% said they would spend 15 minutes or less, while 77%
said they would not exceed 30 minutes. Thus, there seemed to be a striking disjunction
between the amount of information to be disclosed and the time investigators thought they
could make available to disclose it.
Based on these findings and as explained further below, it seems clear to us that routine
approaches to informed consent are not likely to be effective in genomic research in which
the prospect of incidental findings exists. Insuring that participants’ decisions are informed
and meaningful will require innovative approaches to dealing with the consent issue.
Models of Informed Consent for Return of Incidental Findings
Drawing on our review of the literature on return of incidental findings and the responses of
the researchers and participants we interviewed, we have identified four prototypical models
of a consent process for return of incidental findings. The first of these reflects the
traditional approach to obtaining consent, while the other three embody creative alternatives.
We describe the advantages and disadvantages of each below. However, we recognize that
there are likely to be multiple permutations of these models, including hybrid approaches
that blur the boundaries between them, and that other models may grow out of the field’s
evolving experience with genomic research. Another alternative, of course, would be not to
return incidental findings at all, obviating the need for any of these models.
Model 1- Obtain consent to return of incidental findings at the time of enrollment into the
genomic research study (“traditional consent” model)
On its face, the most straightforward model of consent to return incidental findings is to
incorporate discussion of the issue into consent to participation in the underlying research.
That is, a portion of the informed consent form and consent discussion—primarily focused
on soliciting the potential subject’s agreement to enter a study involving genome sequencing
—would be set aside for discussion of incidental findings. This discussion would cover the
nature and likelihood of incidental findings; the categories of findings that may be detected;
the options available to participants for return of some, all, or none of the findings; the
benefits and risks associated with return of incidental findings; and associated information,
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such as confidentiality of the data, implications for family members, and how data will be
handled in the event of a participant’s death or disability. After the discussion, participants
would be asked to choose which, if any, results they would want to receive from those
categories that the study has decided to make available to them (e.g., evidence of: serious
conditions that are preventable or treatable, serious conditions that are not medically
actionable but may affect life planning, carrier status, pharmacogenetic status). The decision
would be embodied in the consent form, by means of participants’ signatures or initials.
The advantages of this model are considerable. Consent to all aspects of a genomic research
study would be obtained up-front, so that participants are aware of the major risks, benefits,
and related information that might affect their decisions about entering the study. To the
extent that the prospect of generating certain types of incidental findings might lead
participants to decline participation, e.g., because of concern about potential discriminatory
impact should predispositions for serious disorders be identified, participants have the
opportunity to make that choice at the outset on an informed basis. Conversely, insofar as
the possibility of receiving incidental findings is an incentive for participation, the
dimensions of return of potential findings would be clear. Moreover, from the perspective of
the research team, this discussion would take place as part of a familiar and clearly defined
process that reflects the usual flow of clinical research, i.e., consent is obtained to all study
procedures prior to participants’ entry into a study.
However, there are also substantial disadvantages to incorporating discussions of incidental
findings into the usual consent process. As noted above, investigators and participants
anticipate that a substantial amount of information will need to be communicated to
facilitate informed decisions regarding return of incidental findings—though investigators
appear to be reluctant to set aside more than 15–30 minutes for the purpose. Inevitably, a
consent process that is already lengthy and complicated17 will be extended even further, and
even so the time allocated may be too limited to convey adequately the additional
complexities involved. Similar problems may be evident with informed consent forms for
genomic research, which in our experience already typically range from 10–20 single-
spaced pages, depending on the complexity of the study, with reading levels well in excess
of the usual recommendation (i.e., not to exceed an eighth-grade level). A good deal of
evidence suggests that potential research participants currently receive more, and more
complex, information than they can reasonably assimilate and utilize in their decisions.18
Adding more information into the mix seems a recipe for poorly informed decision making
about return of incidental findings, and may, by virtue of the confusion it engenders,
discourage some potential subjects from participating in the underlying research.
To be sure, some of these problems could be mitigated by providing participants with
information in advance of when their informed consent will be obtained, or having multiple
interactions with them over a period of time (e.g., 1–2 weeks). Written materials could be
supplemented with access to online video or multi-media resources, allowing participants
who so desire to explore the issue in depth prior to the final consent transaction with the
researcher. Guidelines for insuring the quality of such “decision aids” have recently been
developed.19 However, the underlying problem would remain: potential participants will
still be receiving a great deal of information both about the study and possible incidental
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findings over a relatively short interval, and will be asked to make a variety of decisions at a
single point in time.
Model 2: Obtain consent in stages, with brief mention of incidental findings at the time of
initial consent, but with more detailed consent obtained when/if reportable results are
found (“staged consent” model)
One alternative to obtaining consent to return of incidental findings at the time of enrollment
would be to defer the process of decision making about returning them until later in the
process. One could, for example, initially obtain consent for participation in a genomic
sequencing study, then at some later point have a second conversation specifically to help
people understand the types of incidental findings that may arise and to make choices
regarding which of the available data they would like to receive. Approaches like this have
been used in non-genomic pediatric cancer studies to allow sequential consideration of
decisions that need to be made.20 Alternatively, one could postpone the process regarding
decisions about receipt of incidental findings until it is clear whether there will be such
findings for a given participant. The likelihood of such findings will vary across studies,
depending on the scope of reportable results defined in each protocol. When consent to
participation is obtained, participants would be told of the possibility that incidental findings
might be detected in the relevant categories, and that they will be given an opportunity, if
such results are found, to learn more about them and decide whether to receive them.
Incidental findings would be described at the time of initial study consent in general terms,
along with the system for notification. If incidental findings are discovered, participants can
be reapproached, told that some findings exist, and engaged in a discussion of the risks and
benefits of learning about the results.
One example of this latter variation of the model is Kohane et al.’s “informed cohort”
approach,21 which has been adopted by the Coriell Personalized Medicine Collaborative.22
Although not focused specifically on incidental findings, the project makes sequencing
findings regarding potentially actionable conditions available to research participants. When
a result becomes available, participants are notified by an email that includes “generalities
about the condition” to which the finding relates.23 Prior to deciding whether to view the
result in their individualized web-based portal, participants can access online educational
materials about the condition in question, and have access to genetic counselors and trained
pharmacists for additional information. Participants who decline to receive a particular
finding can return at any subsequent point to do so,24 approximating what has been
described as “self-guided management” of sequencing results.25 A similar model has been
described for the My46 genomic sequencing project at the University of Washington26 and
for direct-to-consumer genome testing.27 (A variant of this approach was adopted by The
Gene Partnership at Children’s Hospital in Boston where participants can indicate in
advance the general categories of findings they would like to receive and are contacted only
with regard to those results.28)
Staged consent of this sort enhances the efficiency of the initial consent process by allowing
participants to focus on the core question of whether to join the genome sequencing study,
apart from issues related to the return of incidental findings about which they can decide at a
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later point. Additional efficiencies can be obtained by postponing the discussion of options
related to return of incidental findings until such findings are detected, entirely eliminating
the need for such discussions with participants for whom no returnable incidental findings
will be found. Participants’ ultimate decisions may be better informed with this approach,
since detailed information specific to the findings in question can be provided when
decisions need to be made. At that point, participants may be more motivated to attend to the
information and focus on the decision, knowing that something has been discovered and a
choice must be made, than they would be at the inception of their participation, when other
decisions must be made as well. Decisions can also be based on their current personal,
medical and familial status, any of which may have changed from the time of enrollment.
On the other hand, the disadvantages associated with this model are real. Participants may
be consenting to the sequencing study without full appreciation of the subsequent choices
with which they will be faced—which arguably may undercut the meaningfulness of their
consent. For this reason, some IRBs and investigators may be discomforted by this
approach. In addition, when consent is deferred until findings are in hand, the very act of
reapproaching participants, whether by email or in person, will suggest or reveal information
that participants may not want to have. Communicating, for example, that the study has
detected an incidental finding regarding a propensity for heart disease may, in a real sense,
preempt a participant’s decision as to whether he or she wants to know about cardiac risks.
For people who may experience distress and anxiety at the prospect of future illness, even if
they decline further information at that point, the harm has already been done. Indeed,
insofar as participants choose not to learn more about the finding, they may actually
exaggerate the degree of risk or inability to affect the outcome, compounding the negative
impact. Although this problem can be mitigated by providing increasingly specific
information in sequential communications (e.g., indicating first that a finding is available
and only providing additional information if a person wants to know more), it cannot be
entirely eliminated. Finally, from a practical perspective, the success of this variant of the
model is dependent on the availability of efficient means of recontacting participants—such
as the web-based portals that several of the projects referenced above have developed.
However, the development of such portals requires considerable up-front capital investment
that many researchers and research institutions may not be able to afford.
Model 3: Obtain consent to return of specific categories of incidental findings at the time
of—and as a condition of—enrollment (“mandatory return” model)
To this point, the models presented have been based on the assumption that participants will
be able to choose which incidental findings to receive—at least within those categories of
reportable results specified in the protocol. However, a recent set of recommendations by the
American College of Medical Genetics and Genomics,29 although made specifically with
regard to clinical genomic testing, suggests a different approach in genomic research as
well.30 The ACMG recommends that at the time of consent to clinical genomic testing,
regardless of the indication, patients be told that certain categories of actionable findings
(mutations in 56 genes were specified, although the ACMG held out the possibility of
revising the list in the future) would be returned automatically. The rationale for the
recommendation was that actionable findings from other medical testing (e.g., radiological
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studies), even if made incidentally, are routinely provided to patients’ clinicians, so that
appropriate measures can be pursued to protect patients’ well-being. The authors of the
ACMG recommendations urged that genomic testing be considered in the same light as
other medical tests and that laboratories report the specified categories of findings
accordingly. A variant of this approach might involve informing participants that some
actionable results will be returned, without necessarily limiting returnable findings to a
particular list of genes; or the indications for mandatory return could be expanded to include
selected findings with implications for the potential offspring of reproductive age
participants (e.g., identification of serious X-linked recessive disorders in female carriers).
The ACMG’s recommendations have attracted a good deal of reaction pro and con31 and
their application to genomic research, in which researchers may have different duties
towards participants than clinicians do towards patients, is arguable. (We acknowledge that
the boundaries between research and clinical care blur in many genomic studies, especially
when the goal is to test the utility of genome sequencing as part of clinical care.) However,
advocates of this model may be able to point to a number of benefits. The consent process at
the time of enrollment will be simplified, since potential participants will not need to make
choices about which results they want to receive. They can be told simply that certain
findings will be communicated, and if they are discovered to have the mutations in question,
additional information will be provided at that time. Researchers will have the clarity that
many of them desire with regard to the precise scope of their obligations. People being
recruited for such studies will retain a degree of choice: if the prospect of receiving results
about, e.g., potentially serious but actionable conditions, is sufficiently distressing, they can
elect to forgo participation. Indeed, that option may be more acceptable with regard to
participation in a research study than in the clinical setting to which the ACMG
recommendations apply, since research participants are less likely to be faced with the
choice of giving up potentially useful medical care.
The primary downside of this model relates to its restriction of individual choice. Research
participants cannot exercise discretion with regard to those findings they desire to receive
and those they would rather not know about, leading to disclosures that may be both under-
and over-inclusive given their preferences. Thus, a woman with a family history of breast
cancer may be well aware of her increased risk of breast cancer but have made a considered
decision to avoid knowing whether she carries a mutation in one of the BRCA1/2 genes.
Although many people might choose differently, the substantial percentage of women at risk
who decline to undergo BRCA1/2 testing suggests that her choice is not unique.32 However,
if BRCA1/2 are on the list of incidental findings that automatically will be returned to
participants (as in the ACMG recommendations), her only option may be to forgo
participation. (A modification of this approach that allowed participants to opt-out of
receiving particular findings would mitigate this problem—but has not been adopted by the
ACMG.) Requiring agreement to return of certain results as a condition of participation may
therefore diminish the willingness of some people to enter genomic research. When that
research offers unique opportunities to advance individual health, as may be the case in
studies of the implementation of genomic medicine, both the person and our broader society
may be worse off by depriving participants of choice. Moreover, this model shares some of
the problems associated with the traditional consent model, i.e., considerable information
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regarding possible findings and how they would be dealt with will need to be provided as
part of the original consent process.
Model 4: Refer participants to third parties for consent and return of incidental findings
(“outsourced” model)
Models 1, 2, and 3 presume that investigators in genomic research studies will decide which
incidental findings to make available to participants, and will at some point seek consent of
some sort for return of those findings. However, an entirely different approach can be
envisioned that places the discretion to determine which results to receive in the hands of
participants themselves. Several of the respondents to our survey of genomic investigators
suggested that participants be given the raw data from their genome sequencing, e.g., on a
USB drive. They would be told that they could take the data to a genetic specialist of their
choosing and, together with that person, decide which, if any, results they choose to receive.
In essence, this model outsources the data analysis and consent process to genetic experts
outside the research team.
The reasons why this approach may be appealing to investigators are evident in the many
concerns expressed in the literature and by the researchers we surveyed and interviewed
about the time and cost likely to be associated with the return of incidental findings.33 The
traditional and staged consent models described above require that detailed information be
provided to participants so that they can decide whether to consent to receive results, and
even the mandatory return model requires some degree of additional disclosure. Screening
for and interpreting reportable incidental findings—however they may be defined in a given
study—requires substantial time and effort, especially when the variants detected have not
previously been reported or their significance is uncertain.34 Once identified, research
findings may need to be confirmed in CLIA-certified laboratories, at additional cost to the
project. Recontacting participants is likely to be time-consuming, unless an investment has
been made in an internet-based system. Communicating results to participants may be
difficult for non-clinically trained investigators, requiring them to hire additional clinical
staff, and even for clinician-investigators will take time that might otherwise be devoted to
advancing the research; doing so without a clinical infrastructure in place to contextualize
and follow up on them may actually be harmful. All of these costs can be foregone by
simply turning the data over to participants and allowing them to proceed as they choose.
Participants, as well, may find advantages in this approach. Their decision making about
participation in a genomic research study will be simplified by separating it entirely from the
question of whether they desire return of incidental findings, a burden that some participants
may find overwhelming. They may still have to be told something about the nature of
potential incidental findings and the information they will receive, but more detailed
information could be transmitted in written form when the raw data are provided. For those
who choose to participate in the study, rather than having others decide which results they
are entitled to access, the choice will be in their hands. People who are averse to information
regarding health risks can put the USB drive with their sequence data in the back of a desk
drawer and forget about it, or retrieve it only at some later point, when the information it
contains may be relevant to a particular medical decision. Those participants who choose to
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know something about the findings will no longer have to rely on the investigators, who
may not be well-informed about the implications of the full range of findings, but can
choose an expert in genetics whom they trust to interpret the data. Although it may not be
easy to find such services today, should a substantial number of researchers (and perhaps
even clinical centers) adopt this approach, services are likely to develop to meet the demand,
analogous to the current commercial availability of direct-to-consumer genomic testing.
Moreover, such services will have an incentive to employ staff with strong communication
skills, which some researchers may not have.
For all the advantages of this model, there are also some deeply unsettling aspects to it.
Especially at present, participants may not have access to resources for appropriate
interpretation of raw genomic data, allowing the research team to avoid the burdens of
returning incidental findings without realistic alternatives being available. Moreover, given
that interpretive services and confirmatory testing (which may be necessary for research data
generated in facilities that lack CLIA-certification) are likely to be costly, poorer
participants may be unable to afford them, creating an issue of social equity in the treatment
of research participants and accentuating disparities in our healthcare system. Participants
will need to incur that cost before they know the likelihood that a potentially useful (or
indeed any) incidental result exists. If, as some have argued, researchers acquire ancillary
obligations to the participants in their studies,35 which may extend to the return of
actionable information, insofar as these responsibilities are outsourced investigators may fail
to fulfill their duties to participants.
Picking a Model
None of the possible models for informed consent to return of incidental findings in
genomic research is ideal. Each manifests a diverse set of advantages and disadvantages,
presenting investigators and IRBs with complex choices. How might decision makers
choose among these approaches? We suggest two criteria that might be considered:
consistency with researchers’ ethical obligations and practicality—and we illustrate how
they might be applied.
Criterion 1: Consistency with researchers’ ethical obligations
The ethical obligations of researchers are generally recognized, at a minimum, as reflecting
the duties of respect for persons, beneficence and justice.36 In the context of consent for
genomic studies, respect for persons at least requires the provision of sufficient information
for participants to make informed and meaningful choices. All of the models are consistent
with that goal. But something more may be required by respect for persons than merely
providing the information: a disclosure process that affords participants a reasonable
opportunity to comprehend the information being provided. In the end, this is an empirical
question, i.e., which model best educates participants about the choices they face? Although
at present we lack the data to answer that question, there are a priori reasons to be
concerned about the traditional consent, mandatory return, and outsourced models in this
regard. In the traditional consent model, even if optimized by providing additional
educational materials in advance or allowing a more extended period for participant
education, participants will be expected to assimilate and make choices based on a large
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amount of information that relates both to the primary study they are being asked to consider
and to the possible return of incidental findings. The ability of most research participants to
do that appears questionable. By depriving participants of the opportunity to choose whether
to receive incidental findings, and which to receive, the mandatory return model limits their
decisional autonomy, a prime consideration in respect for persons. Finally, although the
outsourced model maximizes participants’ choices, unless participants can be directed to
reliable interpretative services, the outsourcing approach leaves investigators uncertain as to
exactly what information will be given to participants by the services to which they turn; if
potentially actionable data that would have been disclosed by the investigators is not
identified by the interpretive service, this approach may leave participants without the
information they would need to take appropriate protective measures.
Beneficence in the research context has been described as the duty to “maximize possible
benefits and minimize possible harms.”37 Each model envisions returning potentially useful
results to participants, thereby meeting one of the desiderata of beneficence. However, the
mandatory return model limits the scope of possible benefits by an a priori decision to
restrict return of incidental findings to those that the investigators consider sufficiently
medically actionable. Although medical knowledge that allows the implementation of
prophylactic measures is obviously valuable, it is clear from interviews with research
participants and with members of the public that they see benefits in obtaining other classes
of information as well.38 For example, data helpful for reproductive decision making for
participants or their children are highly valued, and many participants would also choose to
receive pharmacogenetic information. Indeed, even incidental findings identifying risks for
unpreventable and untreatable disorders (e.g., Alzheimer’s disease) can be useful to people
who desire to incorporate such information in major life decisions.
The minimization of harm component of beneficence might be met both by providing
information that allows participants to take protective measures against identified medical
risks and by avoiding the psychosocial harms that may be associated with the receipt of
upsetting genetic information. Those two considerations may be in tension with one another,
since some participants may be upset by data that in principle would allow them to take
more effective prophylactic or treatment measures. Each of the models deals with this in
some way: the traditional and outsourcing models put the decision about how to balance
these considerations in the hands of participants, thus reducing the risk that they will receive
information they would find upsetting, whereas the mandatory return model leaves the
decision to the researchers, thereby decreasing the risk that actionable information will not
be revealed. Staged approaches allow participants to retain control, but when a decision is
deferred until findings exist, the door is open to communication of unwanted information
about potential risks. Neither giving priority to avoiding medical risks nor favoring the
avoidance of psychosocial risks is necessarily superior; choosing one over the other is
dependent on how one differentially weights the two sets of concerns.
Justice in the research setting usually has been understood as relating to the fair distribution
of benefits and burdens.39 Here, the outsourced model is of concern. By outsourcing the
consent process, along with the interpretation and reporting of incidental findings, this
model reinforces the disparities in access to medical services based on wealth that
Appelbaum et al. Page 11













characterize much of our health care today. Participants who can afford to seek out private
services to interpret the genomic findings will have the benefit of such information. Poorer
participants, who make the same contribution to genomic research, will be left only with a
USB drive containing what is, for them, uninterpretable and therefore useless data. It should
be noted as well that under any of these models participants without health insurance
coverage or other resources to take advantage of the information they receive may similarly
be deprived of the benefits that their incidental findings could convey.
Criterion 2: Practicality
Practicality is yet another consideration in judging these models. The effectiveness of an
enhanced version of the traditional consent model and of the staged consent model is
dependent in part on the availability of funding to create the infrastructure on which they
depend: educational materials, including video and multimedia resources for traditional
consent, and a system for communicating with participants, soliciting preferences and
returning information over time for staged consent. From the researcher’s perspective,
outsourcing may seem the most practical, since it removes the burden of dealing with
incidental findings from the research team. However, in the absence of readily accessible
interpretive genetic services, the outsourced model cannot function at all. To some extent,
availability of the resources needed to interpret genomic data, now the most costly aspect of
genome sequencing,40 and to deliver the findings to participants in a sensitive and
understandable manner affect all of the models. As better pipelines based on improved
databases and bioinformatic algorithms are developed to identify pathogenic variants, some
of the attractiveness of mandatory return of a limited set of findings may fade as the burden
on researchers of interpreting the data diminishes. The outsourcing approach may become
less attractive for the same reason, although there may still be an advantage in turning to
experts skilled in discussing genomic findings with participants.
Conclusion
At present, there is no optimal solution for the dilemma of how best to obtain consent for
return of incidental findings in genomic research. Clarification of the relative virtues of the
various models—and the hybrid models that are likely to develop—will depend in part on
researchers’ evaluations of their efficacy—work that would appear to be the next logical
step in this area. Among the variables that might productively be explored in future research
that compares these models are: the nature and scope of information communicated;
participants’ comprehension, ease in decision making, and satisfaction with the process; and
the time and resource burdens on researchers and prospective participants. But selection of
an approach also requires consideration of normative implications, and here trade-offs are
inevitable. Finally, we emphasize that in this rapidly changing area of research new and
better models for consent may develop, and as genomic research evolves, the balance of
practicalities is likely to change as well. No one model is likely to represent the permanent
solution to the challenges of obtaining meaningful consent for the return of incidental
findings.
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Table 1
Potential Advantages and Disadvantages of Models of Consent to Return of Incidental Findings
Model Name Potential Advantages Potential Disadvantages
1. Traditional Consent - Resembles traditional process, familiar to the
research community
- Participant receives all IF information prior to
deciding whether to participate
- Participant maintains choice about types of IFs to
receive, or about opting out
- Adds time and information to
lengthy and complex process
- Participant preferences may
change after initial consent
2. Staged Consent - Reduces time spent discussing IFs during initial
consent; more detailed information provided later if
IFs occur
- Participant makes decisions on IFs closer to the time
of receipt, can consider current circumstances
- More detailed and specific information for
participant
- Participant maintains choice about types of IFs to
receive, or about opting out altogether
- Following-up and recontacting
participants for consent could be
costly and burdensome
- Participant’s decision to enroll in
study made without full
information about potential
return of IFs
- Depending on procedure,
recontacting participant may
reveal unwanted information
about an IF, with negative impact
on participant
3. Mandatory Return - Simplifies consent at enrollment: participant receives
information only on selected IFs, does not have to
choose which findings to receive
- Researchers’ obligations to return IFs clearly defined
and limited to a pre-determined list
- Degree of choice maintained about whether to
participate in the study
- Participant choice restricted—
cannot choose which findings to
receive, and cannot refuse to
accept designated findings
- Lack of participant choice may
be disincentive to enroll in
genomic research
- Efforts to follow-up and
recontact participants could be
costly and burdensome for
researchers
4. Outsourcing - Researchers don’t have to spend time explaining
implications of IFs - would be outsourced to entities
that specialize in interpretation/ communication of
genomic information
- Costs associated with return of results
avoided, including recontacting
participants, hiring additional staff to
communicate results, etc.
- Participant spared immediate task of deciding which
secondary findings to receive; can pursue this
question later with entity of their choice
- Researchers’ obligations simplified to the return of
each participant’s raw data
- Though participant receives all
genomic data, may not become
aware of medically significant
data
- Services for genomic
interpretation and counseling not
widely available at present—
could be mitigated if demand
increases
- May exacerbate health
disparities, since further
interpretive services may be
costly and hence limited to
wealthy participants
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